Conference Coverage
Conference Coverage
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.
Conference Coverage
Studies need to address best follow-on therapy to ibrutinib in CLL
There was no clear standard treatment approach for patients with CLL who discontinued ibrutinib or for whom ibrutinib did not work, in a...
Conference Coverage
Debate: Is MRD ready for prime time in multiple myeloma?
NEW YORK – Two leading multiple myeloma experts question whether it’s time to incorporate minimal residual disease measures into daily practice....
Conference Coverage
Is MRD ready for prime time in multiple myeloma?
NEW YORK, NY—Speakers faced off over the issue of minimal residual disease (MRD) testing in multiple myeloma (MM) at Lymphoma & Myeloma 2017....
Conference Coverage
Idelalisib efficacy against CLL tarnished by toxicity
Only one in five patients on idelalisib in registration trials remained on the drug after 2 years.
Conference Coverage
Deep remission or long-term control? Choice is key in early CLL
Sequencing therapy in chronic lymphocytic leukemia depends on patient characteristics, prior therapy, frailty, and mutations.
Conference Coverage
Biosimilar matches rituximab in large follicular lymphoma trial
MADRID – The biosimilar GP2013 met the criteria for therapeutic equivalence to rituximab in a large comparator trial of previously untreated...
Conference Coverage
Biosimilar deemed equivalent to reference drug in FL
MADRID—The biosimilar GP2013 has demonstrated equivalence to its reference drug rituximab in patients with previously untreated, advanced-stage...
Conference Coverage
M13-982 trial in del(17p) CLL: High, durable response rates to venetoclax
Venetoclax monotherapy is well tolerated and associated with high and durable objective response rates in patients with del(17p) CLL, according to...
News
IMiD/Anti-CD20 combo induces complete responses in r/r NHL
Lugano, Switzerland – A combination of obinutuzumab (Gazyva) and the experimental immunomodulatory agent CC-122 showed “clinically meaningful”...